www.tickerreport.com ·
Zura Bio Nasdaqzura Releases Earnings Results Misses Estimates by 0 05 Eps
Topic context
This topic has been covered 376273 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedZura Bio, a clinical-stage biotechnology company, missed Q1 2026 EPS estimates by $0.05, triggering a 7.2% stock decline. The miss reflects higher-than-expected R&D or operating expenses, squeezing margins for this pre-revenue biotech. No product revenue or supply chain impact; the commercial mechanism is limited to equity valuation and financing risk for the company. Impact is single-company-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Zura Bio (NASDAQ:ZURA) reported EPS of ($0.22), missing consensus estimate of ($0.17) by $0.05.
- Stock fell 7.2% to $4.54, market cap $430.76 million.
- Oppenheimer lowered target price to $15.00; Weiss Ratings issued 'sell' rating.
- Institutional investors hold 61.14% of shares; JPMorgan Chase & Co. recently purchased.